Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422337 | 0.86 | SMN1; SMN2 (0.73) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL5879030 | 0.84 | RAB9A (0.88) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL10941324 | 0.84 | NAMPT (0.69) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4289783 | 0.84 | HPGD (0.71) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL10943445 | 0.84 | RAB9A (0.88) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL9877349 | 0.83 | TSHR (0.67) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL9671985 | 0.83 | TSHR (0.77) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL8633952 | 0.83 | SMN1; SMN2 (0.68) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4952046 | 0.82 | TSHR (0.61) | TSHRRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL784330 | 0.82 | TSHR (0.61) | TSHRRAB9ASMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | claimed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| US-7531540-B2 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2007-06-07 | — | — | US | disclosed |
| US-7179810-B2 | Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders | ALTANA PHARMA AG (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2005-10-20 | — | — | US | disclosed |
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | disclosed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | disclosed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | TSHR 1988/4885RAB9A 1718/4885SMN1; SMN2 3796/4885 |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE5A | TSHR 3389/4885RAB9A 1893/4885SMN1; SMN2 2844/4885 |
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | TSHR 3668/4885RAB9A 2280/4885SMN1; SMN2 3235/4885 |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | TSHR 3668/4885RAB9A 2280/4885SMN1; SMN2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.